Incyte (INCY) just paired its push beyond JAKAFI with fresh news in colorectal cancer. A new phase II collaboration with Natera centers on INCA33890 and MRD-guided patient selection using Signatera. ...
Source LinkIncyte (INCY) just paired its push beyond JAKAFI with fresh news in colorectal cancer. A new phase II collaboration with Natera centers on INCA33890 and MRD-guided patient selection using Signatera. ...
Source Link
Comments